The Medicines Company (NASDAQ:MDCO) has an average broker rating of 1.13, which is interpreted as a Strong Buy, as rated by 8 equity analysts. Nonetheless, 7 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Ranking by Zacks Investment Research for Coach Inc is 4, which is also a Sell.
The Medicines Company (NASDAQ:MDCO) : 7 investment research analysts covering The Medicines Company (NASDAQ:MDCO) have an average price target of $49.29 for the near short term. The highest target price given by the Brokerage Firm to the stock is $65 and the lowest target is $41 for the short term. Analysts expect the variance to be within $8.22 of the average price.
For the current week, the company shares have a recommendation consensus of Buy.
The Medicines Company (NASDAQ:MDCO): stock turned positive on Tuesday. Though the stock opened at $33.52, the bulls momentum made the stock top out at $34.79 level for the day. The stock recorded a low of $33.5 and closed the trading day at $34.69, in the green by 4.24%. The total traded volume for the day was 826,307. The stock had closed at $33.28 in the previous days trading.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (EVP & Chief Corp. Dev. Officer) of Medicines Co /De, Cox Christopher T, had purchased 45,985 shares in a transaction dated on June 8, 2016. The transaction was executed at $37.62 per share with total amount equaling $1,729,956.
The Medicines Company is a global biopharmaceutical company. The Companys marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Companys products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Companys four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.